Leukemia xenografts can be established using either subcutaneous implantation, which allows tumor growth as solid masses, or systemic injection (often intravenous), which better mimics disseminated leukemia in the bone marrow and peripheral blood. Both approaches provide unique insights: subcutaneous models facilitate tumor volume measurement and histological analysis, while systemic models reflect disease progression and metastasis.

Using these models, researchers can evaluate the pharmacodynamics and pharmacokinetics of experimental drugs, understand tumor-host interactions, and investigate microenvironment influences on leukemia growth and survival. Xenografts also enable testing of immunotherapies, such as monoclonal antibodies and CAR-T cells, in a living system.

Challenges include ensuring the human cells engraft efficiently and recapitulate patient disease features. Advances in mouse strains lacking key immune components have improved engraftment rates and model fidelity.

By bridging the gap between cell culture and clinical trials, leukemia xenograft models provide critical data that guide drug development, dosing strategies, and combination therapy designs. They help reduce the risk of late-stage drug failure by providing early efficacy signals in a relevant biological context.

References: Altogen.com Altogenlabs.com

The post In Vivo Leukemia Models: How Xenografts Are Changing Preclinical Oncology appeared first on Blood Transfection.

At the cellular level, AML cells display a block in differentiation and high proliferative capacity, while CML cells maintain more mature phenotypes with aberrant signaling. These differences influence their response to genetic manipulation and drug treatments.

Understanding these distinctions guides researchers in selecting appropriate cell models, designing transfection protocols, and interpreting experimental results. For example, the K562 cell line, derived from a CML patient, expresses BCR-ABL and is widely used for studying tyrosine kinase inhibitors, whereas HL-60 cells serve as a model for AML differentiation and apoptosis studies.

References: Altogen.com Altogenlabs.com

The post Understanding the Differences Between AML and CML at the Cellular Level appeared first on Blood Transfection.

The most common delivery method for CRISPR components in suspension cells is electroporation, which transiently permeabilizes the membrane, allowing direct entry of Cas9 protein, guide RNA, or plasmid DNA. Optimization of electroporation parameters—such as voltage, pulse duration, and buffer composition—is essential to balance editing efficiency and survival. Using ribonucleoprotein complexes (preassembled Cas9 protein with guide RNA) reduces off-target effects and improves editing speed.

Common troubleshooting steps include verifying cell viability before and after electroporation, ensuring high-quality nucleic acid preparations, and confirming guide RNA efficiency in silico. Post-editing, researchers must carefully select clones or enrich edited populations using fluorescence-activated cell sorting (FACS) or antibiotic selection.

Successful CRISPR editing in blood cancer models enables functional studies of oncogenes, tumor suppressors, and drug resistance genes, advancing targeted therapy development.

References: Altogen.com Altogenlabs.com

The post CRISPR Editing in Suspension Cells: Techniques and Troubleshooting appeared first on Blood Transfection.

In leukemia research, siRNA knockdown helps dissect the roles of oncogenes, tumor suppressors, signaling molecules, and resistance factors, advancing our understanding of cancer biology and supporting the development of targeted therapies.

One of the most studied genes in acute myeloid leukemia (AML) is FLT3, a receptor tyrosine kinase involved in hematopoietic cell proliferation and survival. Mutations in FLT3 occur in roughly 30% of AML patients and are associated with poor prognosis. siRNA-mediated FLT3 knockdown in AML cell lines has been instrumental in validating FLT3 inhibitors and exploring resistance pathways.

NPM1 is another critical gene in AML. Mutations here disrupt nucleolar function and contribute to leukemogenesis. Using siRNA to silence mutant NPM1 in cell lines helps researchers analyze its role in proliferation and apoptosis.

In chronic myeloid leukemia (CML), the BCR-ABL fusion gene created by the Philadelphia chromosome is the primary driver of malignant transformation. Targeting BCR-ABL with siRNA confirms the efficacy of tyrosine kinase inhibitors and helps investigate secondary mutations responsible for drug resistance.

T-cell leukemias often show dysregulation in genes like NOTCH1, a receptor involved in T-cell development and survival. siRNA knockdown of NOTCH1 has provided insight into its oncogenic role and potential as a therapeutic target.

Other notable targets across various leukemia types include JAK1, involved in cytokine signaling; PTEN, a tumor suppressor regulating cell growth; and MYC, a transcription factor with widespread roles in cell cycle control.

In lymphomas, genes such as BCL2, which regulates apoptosis, and CD19, a B-cell surface marker, are frequently silenced to evaluate their contribution to tumor survival and to test antibody-based therapies.

siRNA combined with electroporation or other optimized delivery methods enables rapid, transient gene silencing without permanent genomic alteration. This flexibility makes siRNA an indispensable tool for functional genomics, target validation, and screening in leukemia research.

Overall, selecting appropriate gene targets and delivering siRNA efficiently into leukemia cells remains a cornerstone of molecular oncology, paving the way for new therapeutic discoveries.

References: Altogen.com Altogenlabs.com

The post Top Genetic Targets for siRNA Knockdown in Leukemia Research appeared first on Blood Transfection.

Lipofection uses cationic lipid molecules to form complexes with negatively charged nucleic acids, facilitating their uptake into cells primarily through endocytosis. This method is widely used in adherent cell lines due to its ease and minimal equipment requirements. However, when applied to suspension blood cells, especially leukemia cells, lipofection faces significant drawbacks.

The suspension nature of blood cells limits interaction with lipoplexes, reducing transfection efficiency. Additionally, leukemia cells often possess active immune signaling pathways that detect and degrade foreign lipid-DNA complexes, triggering inflammatory or apoptotic responses. The net result is often low gene delivery, high cytotoxicity, and inconsistent results.

In contrast, electroporation physically opens transient pores in the cell membrane by applying controlled electrical pulses. These pores allow direct entry of nucleic acids into the cytoplasm, bypassing endocytotic and immune barriers. Electroporation has proven effective across numerous blood cancer cell lines such as Jurkat, K562, HL-60, and CCRF-CEM.

The main challenges with electroporation include the need for precise optimization. Excessive voltage or prolonged pulses can cause irreversible membrane damage and cell death, while insufficient parameters yield poor transfection. Buffer composition is equally important; specialized electroporation buffers maintain osmolarity and ion concentrations conducive to cell survival and nucleic acid delivery.

Best practices for electroporating leukemia cells include using freshly cultured cells in exponential growth phase, optimizing cell density, and employing commercially available kits validated for specific cell lines. Post-electroporation recovery in nutrient-rich media under optimal temperature conditions enhances cell viability.

In many cases, electroporation yields transfection efficiencies exceeding 70%, with high cell viability, making it the preferred method for gene editing, siRNA knockdown, and protein expression studies in hematologic research.

For laboratories working on leukemia models, combining electroporation with high-quality reagents and rigorous protocol adherence ensures reproducible, efficient gene delivery, accelerating discovery and therapeutic development.

References: Altogen.com Altogenlabs.com

The post Electroporation vs. Lipofection: Best Practices for Leukemia Cells appeared first on Blood Transfection.

Their high proliferation rate and immunologic origin also mean that these cells may activate strong stress responses or apoptosis pathways when exposed to foreign genetic material. This limits transfection efficiency and increases cytotoxicity, particularly when introducing large plasmids or high concentrations of siRNA.

Electroporation has emerged as the most effective method for these cell types, allowing brief permeabilization of the cell membrane using electrical pulses. However, even electroporation requires careful optimization of buffer composition, voltage parameters, and cell density to achieve high viability and transgene expression. Using cell-type–specific kits and validated protocols can significantly increase success rates when working with blood cancer models.

References: Altogen.com Altogenlabs.com

The post What Makes Blood Cell Transfection So Challenging? appeared first on Blood Transfection.

In co-transfection, two or more different plasmids are mixed together with the transfection reagent and introduced into the cells. Each plasmid contains a different gene of interest, allowing for the simultaneous expression of multiple genes in the same cell. The ratio of the different plasmids used in co-transfection can be adjusted to achieve the desired levels of gene expression.

Co-transfection has several advantages:

1. Efficiency: Co-transfection can be more efficient than sequentially transfecting cells with different plasmids, as it reduces the overall manipulation and stress on the cells.
2. Functional studies: Co-transfection can be used to study the interaction between two or more proteins, or to reconstitute a multi-protein complex.

However, there are also challenges and limitations associated with co-transfection:

1. Expression levels: It can be challenging to control the relative expression levels of the different genes, as this can be influenced by factors such as the ratio of the plasmids, the strength of the promoters, and the efficiency of the transfection reagent.
2. Variability: There can be variability in the number of copies of each plasmid that get inside each cell, leading to variability in gene expression between cells.
3. Size limitation: The size of the plasmids can affect the efficiency of co-transfection. Larger plasmids are generally more difficult to transfect.

Despite these challenges, co-transfection is a valuable tool in molecular biology and can be achieved with many of the same transfection reagents used for single-gene transfection. As always, it’s important to carefully design and control experiments to account for potential variability and to optimize conditions for the best results.

The post Co-transfection and multi-gene expression using DNA transfection reagents appeared first on Blood Transfection.

The post Recent advancements and future perspectives in DNA transfection reagents. appeared first on Blood Transfection.

CRISPR-Cas9 System:

CRISPR-Cas9 is a two-component system that consists of the Cas9 nuclease and a guide RNA (gRNA). The gRNA is designed to match the sequence of the target DNA and guides the Cas9 nuclease to the specific location in the genome where a cut should be made. Once the DNA is cut, the cell’s natural DNA repair mechanisms are activated. These repair processes can be harnessed to introduce desired genetic changes.

Transfection in the CRISPR-Cas9 System:

To use the CRISPR-Cas9 system for gene editing, the components of the system (the Cas9 nuclease and the gRNA) need to be delivered into cells. This is where transfection comes in. The Cas9 and gRNA can be encoded on plasmids and transfected into cells using a variety of transfection reagents. Alternatively, the Cas9 protein and gRNA can be complexed together to form a ribonucleoprotein (RNP) complex, which can be delivered directly into cells using certain transfection reagents.

Here are some common methods for delivering CRISPR-Cas9 components into cells:

1. Lipid-Based Transfection: This is a commonly used method for transfecting plasmids encoding Cas9 and the gRNA into cells. The plasmids are mixed with a lipid-based transfection reagent that forms complexes with the DNA. These complexes can then enter cells via endocytosis.
2. Electroporation: This method uses an electric field to transiently permeabilize the cell membrane, allowing the plasmids or the Cas9 RNP complex to enter the cell.
3. Microinjection: This method involves directly injecting the Cas9 and gRNA into the cell. While this method is labor-intensive and requires specialized equipment, it can be highly efficient and is often used for certain applications, such as creating genetically modified animals.
4. Viral Vectors: Lentiviral or adeno-associated viral vectors can be used to deliver the Cas9 and gRNA into cells. This method can be highly efficient and is often used for hard-to-transfect cells or for in vivo applications.

It’s important to note that each of these methods has its advantages and disadvantages, and the best method can depend on various factors, such as the cell type, the specific experimental goals, and the resources available. As always, careful experimental design and optimization are key to successful gene editing experiments.

The post Gene editing using DNA transfection reagents (e.g., CRISPR-Cas9 system) appeared first on Blood Transfection.

1. Monogenic Disorders: These are diseases caused by mutations in a single gene. The goal of gene therapy for these diseases is to introduce a correct copy of the faulty gene into the patient’s cells. Examples include cystic fibrosis, hemophilia, Duchenne muscular dystrophy, and certain forms of blindness.
2. Cancer: Gene therapy can be used to introduce genes that inhibit the growth of cancer cells, stimulate the immune system to attack cancer cells, or make cancer cells more sensitive to other kinds of therapy. Chimeric antigen receptor (CAR) T-cell therapy, where T cells are genetically modified to recognize and attack cancer cells, is one example of a gene therapy for cancer that has seen clinical success.
3. Infectious Diseases: Gene therapy can potentially be used to confer resistance to certain infectious diseases. For example, research is being conducted on gene therapies that could inhibit HIV replication in infected individuals.
4. Neurodegenerative Diseases: Gene therapy could potentially be used to slow the progression of neurodegenerative diseases like Alzheimer’s or Parkinson’s by introducing genes that promote neuron survival or inhibit the aggregation of toxic proteins.

In terms of the types of DNA transfection reagents used in gene therapy, viral vectors are currently the most common method used in clinical applications due to their high efficiency. These include lentiviral vectors, adeno-associated viral (AAV) vectors, and retroviral vectors.

However, non-viral methods of gene delivery are also being actively researched due to certain advantages they offer, such as lower risk of immunogenicity, larger capacity for therapeutic DNA, and potential for repeat dosing. These non-viral methods include lipid-based nanoparticles, polymer-based vectors, and physical methods like electroporation.

It’s important to note that while there has been significant progress in the field of gene therapy, there are still many challenges to be overcome, including issues related to the efficiency of gene delivery, potential side effects, and the long-term stability and safety of the introduced genes. As of my last training cut-off in September 2021, many gene therapies are still in the experimental stages and are subject to ongoing clinical trials to evaluate their safety and efficacy.

The post Gene therapy applications of DNA transfection reagents appeared first on Blood Transfection.